Cover Image

Guidance for industry : biological product deviation reporting for licensed manufacturers of biological products other than blood and blood components.

Bibliographic Details
Corporate Authors:	Center for Biologics Evaluation and Research (U.S.), Center for Drug Evaluation and Research (U.S.)
Format:	Government Document eBook
Language:	English
Published:	Rockville, MD : U.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research : Center for Drug Evaluation and Research, [2006]
Subjects:	Biological products > Government policy > United States.
Online Access:	https://purl.fdlp.gov/GPO/LPS112510

Similar Items

Guidance for industry : changes to an approved application : biological products, human blood and blood components intended for transfusion or for further manufacture.
Published: (2001)

Guidance for industry : biological product deviation reporting for blood and plasma establishments.
Published: (2006)

Guidance for industry : comparability protocols, protein drug products and biological products; chemistry, manufacturing, and controls information.
Published: (2003)

Guidance for industry : recognition and use of a standard for uniform blood and blood component container labels.
Published: (2006)

Guidance for industry : recommendations for assessment of donor suitability and blood and blood product safety in cases of possible exposure to anthrax.
Published: (2001)

Guidance for industry : year 2000 date change for computer systems and software applications used in the manufacture of blood products.
Published: (1998)

Guidance for industry and FDA staff : early development considerations for innovative combination products.
Published: (2006)

Guidance for industry : assessing donor suitability and blood and blood product safety in cases of known or suspected west Nile virus infection.
Published: (2005)

Guidance for industry : clinical studies section of labeling for human prescription drug and biological products, content and format.
Published: (2006)

Guidance for industry : recommendations for deferral of donors and quarantine and retrieval of blood and blood products in recent recipients of smallpox vaccine (vaccinia virus) and certain contacts of smallpox vaccine recipients.
Published: (2002)

Guidance for industry : pre-storage leukocyte reduction of whole blood and blood compoments intended for transfusion.
Published: (2001)

Guidance for industry for the submission of chemistry, manufacturing and controls and establishment description information for human blood and blood components intended for transfusion or for further manufacture and for the completion of the form FDA 356h "Application to market a new drug, biologic or an antibiotic drug for human use".
Published: (1999)

Guidance for industry : revised preventive measures to reduce the possible risk of transmission of Creutzfeldt-Jakob disease (CJD) and variant Creutzfeldt-Jakob disease (vCJD) by blood and blood products.
Published: (2002)

Guidance for industry : amendment (donor deferral for transfusion in France since 1980) to "Guidance for industry, revised preventive measures to reduce the possible risk of transmission of Creutzfeldt-Jakob disease (CJD) and variant Creutzfeldt-Jakob disease (vCJD) by blood and blood products".
Published: (2006)

Guidance for industry : bar code label requirements, questions and answers.
Published: (2006)

Guidance for industry : revised recommendations for the assessment of donor suitability and blood product safety in cases of suspected severe acute respiratory syndrome (SARS) or exposure to SARS.
Published: (2003)

Guidance for industry : IND meetings for human drugs and biologics, chemistry, manufacturing, and controls information.
Published: (2001)

Guidance for industry : submitting type V drug master files to the Center for Biologics Evaluation and Research.
Published: (2001)

Guidance for industry : clinical pharmacology section of labeling for human prescription drug and biological products : content and format.
Published: (2009)

Guidance for industry : availability of licensed donor screening tests labeled for use with cadaveric blood specimens.
Published: (2000)

Guidance for sponsors, industry, researchers, investigators, and Food and Drug Administration staff : certifications to accompany drug, biological product and device applications/submissions : compliance with Section 402(j) of the Public Health Service Act, added by Title VIII of the Food and Drug Administration Amendments Act of 2007.
Published: (2009)

Guidance for industry : Q5E comparability of biotechnological/biological products subject to changes in their manufacturing process.
Published: (2005)

Guidance for industry : reports on the status of postmarketing study commitments : implementation of section 130 of the Food and Drug Administration Modernization Act of 1997.
Published: (2006)

Guidance for industry : good pharmacovigilance practices and pharmacoepidemiologic assessment.
Published: (2005)

Guidance for industry : providing regulatory submissions in electronic format, content of labeling.
Published: (2005)

Guidance for industry : precautionary measures to reduce the possible risk of transmission of zoonoses by blood and blood products from xenotransplantation product recipients and their contacts.
Published: (1999)

Guidance for industry : use of serological tests to reduce the risk of transmission of trypanosoma cruzi infection in whole blood and blood components for transfusion and human cells, tissues, and cellular and tissue-based products (HCT/Ps).
Published: (2009)

Guidance for industry : development and use of risk minimization action plans.
Published: (2005)

Guidance for industry : FDA export certificates.
Published: (2005)

Guidance for industry : precautionary measures to reduce the possible risk of transmission of zoonoses by blood and blood products from xenotransplantation product recipients and their intimate contacts.
Published: (2002)

Guidance for industry : Q6B specifications : test procedures and acceptance criteria for biotechnological /biological products.
Published: (1999)

Guidance for industry : cooperative manufacturing arrangements for licensed biologics.

Guidance for industry : clinical lactation studies; study design, data analysis, and recommendations for labeling.
Published: (2005)

Guidance for industry : notifying FDA of fatalities related to blood collection or transfusion.
Published: (2003)

Guidance for industry : providing regulatory submissions in electronic format, receipt date.
Published: (2007)

Guidance for industry : use of sterile connecting devices in blood bank practices.
Published: (2000)

Guidance for industry : format and content of proposed risk evaluation and mitigation strategies (REMS), REMS assessments, and proposed REMS modifications.
Published: (2009)

Guidance for industry : IND exemptions for studies of lawfully marketed drug or biological products for the treatment of cancer.
Published: (2004)

Guidance for industry : Q5A viral safety evaluation of biotechnology products derived from cell lines of human or animal origin.
Published: (1998)

Guidance for industry : implementation of acceptable full-length donor history questionnaire and accompanying materials for use in screening donors of blood and blood components.
Published: (2006)